Inno-Gene SA
WSE:IGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Inno-Gene SA
Total Current Liabilities
Inno-Gene SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Inno-Gene SA
WSE:IGN
|
Total Current Liabilities
zł2.5m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
|
N
|
Nanogroup SA
WSE:NNG
|
Total Current Liabilities
zł10m
|
CAGR 3-Years
31%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Total Current Liabilities
zł4.5m
|
CAGR 3-Years
105%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Total Current Liabilities
zł61.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
14%
|
|
|
S
|
Selvita SA
WSE:SLV
|
Total Current Liabilities
zł127.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Inno-Gene SA
Glance View
Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
See Also
What is Inno-Gene SA's Total Current Liabilities?
Total Current Liabilities
2.5m
PLN
Based on the financial report for Jun 30, 2024, Inno-Gene SA's Total Current Liabilities amounts to 2.5m PLN.
What is Inno-Gene SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-3%
Over the last year, the Total Current Liabilities growth was 49%. The average annual Total Current Liabilities growth rates for Inno-Gene SA have been -38% over the past three years , -6% over the past five years , and -3% over the past ten years .
